Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the new Neffy treatment for severe allergic reactions will be available on the NHS.

It is critical that medicines used in the United Kingdom are safe and effective. The Medicines and Healthcare products Regulatory Agency (MHRA) assesses all medicines before they can be used in the UK. Neffy (epinephrine nasal spray) has not been licenced by the MHRA. Should an application for it be received, the MHRA will consider the benefit-risk of the product accordingly in regards to its quality, safety and effectiveness. It is the responsibility of the company to apply to the MHRA for a marketing authorisation.

Local National Health Service organisations are expected to make decisions on the availability of medicines based on an assessment of the available evidence and taking into account any relevant national guidance.